SEC Form 4 · accession 0001209191-17-023016
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A Orwin
Director
Period of report
Mar 23, 2017
Accepted (ET)
Mar 27, 2017 · 7:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 23, 2017 | A | 4,375 | $0.00 | A | 4,375 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $17.53 | Mar 23, 2017 | A | 17,500 | A | — | Mar 22, 2027 | Common Stock | 17,500 | 17,500 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in twelve equal quarterly installments following the grant date.